

## Supplementary Information

### Self-Assembled Nanoparticles Formed via Complementary Nucleobase Pair Interactions between Drugs and Nanocarriers for Highly Efficient Tumor-Selective Chemotherapy

Fasih Bintang Ilhami,<sup>a#</sup> Ai Chung,<sup>a#</sup> Yihalem Abebe Alemayehu,<sup>a#</sup> Ai-Wei Lee,<sup>de</sup> Jem-Kun Chen,<sup>bc</sup> Juin-Yih Laj<sup>abf</sup> and Chih-Chia Cheng<sup>ab\*</sup>

- a. Graduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, Taipei 10607, Taiwan.
- b. Advanced Membrane Materials Research Center, National Taiwan University of Science and Technology, Taipei 10607, Taiwan.
- c. Department of Materials Science and Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan.
- d. Department of Anatomy and Cell Biology & Taipei Heart Institute, Taipei Medical University, Taipei, 11031, Taiwan.
- e. Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, 11031, Taiwan.
- f. R&D Center for Membrane Technology, Chung Yuan Christian University, Chungli, Taoyuan 32043, Taiwan.

# These authors contributed equally to this work.

\* Corresponding Author

E-mail: [cccheng@mail.ntust.edu.tw](mailto:cccheng@mail.ntust.edu.tw)

## Experimental Section

### *Chemicals and materials*

Rhodamine 6G (dye content 99 %), poly(propylene glycol) diacrylate (number-average molecular weight,  $M_n$ : ~800 g/mol), uracil (> 99%), adenine (> 99.5% purity), dimethylformamide (DMF), methanol and potassium tertbutoxide were purchased from Sigma-Aldrich (St. Louis, MO, USA) or Acros Organics (Geel, Belgium) at the highest purity available; all other chemicals and reagents were purchased from Sigma-Aldrich at the highest purity available. The synthesis and structural characterization of BU-PPG and A-MA were performed as described in detail in our previous studies.<sup>16,37</sup>

### *Synthesis of A-Propylamine*

A-MA (1 g, 0.0045 mol) and 1,3-diaminopropane (10 g, 0.135 mol) were solved in methanol (100 mL) and reacted at room temperature (~20–25 °C) with stirring under a slow stream of nitrogen until the ester carbonyl peak of A-MA (at 1720-1730  $\text{cm}^{-1}$ ) completely disappeared from the Fourier transform infrared (FTIR) spectra of the monitored samples. Subsequently, the mixture was filtered through filter paper using a Büchner funnel via vacuum suction, and the resulting solution was subjected to vacuum distillation to remove excess 1,3-diaminopropane and methanol. Finally, the residual oil sample was washed several times with tetrahydrofuran and acetone to obtain A-Propylamine as a yellowish white powder, yield 86% (1.02 g).

### *Synthesis of A-R6G*

R6G (0.5 g, 0.001 mol) and A-Propylamine (1.7 g, 0.006 mol) were solved in methanol (50 mL) in a two-neck flask equipped with a stirrer and maintained at 50 °C for one week under a

nitrogen atmosphere. Methanol was removed using a rotary evaporator, then chloroform was added to the crude oil sample and stirred at room temperature for 1 h. The insoluble materials were removed by filtration through a Buchner funnel and the remaining chloroform was removed using a rotary evaporator. Subsequently, the crude sample was refluxed with diethyl ether and cooled to give a reddish-brown precipitate. Finally, the product was washed twice with acetone to obtain A-R6G as a pink powder, yield 75% (0.5 g).

### ***Characterization***

#### ***Fourier transform infrared (FTIR) and proton/carbon nuclear magnetic resonance spectra***

***(<sup>1</sup>H and <sup>13</sup>C NMR)***: The synthesized materials were initially characterized using FTIR on a PerkinElmer Spectrum Two IR spectrometer over the scan range from 600-4000 cm<sup>-1</sup>. Background spectra were obtained to eliminate the effects of atmospheric moisture and carbon dioxide. To elucidate the structures of the products, NMR spectra were recorded using a Bruker AVIII instrument (Billerica, MA, USA) at 500 MHz in deuterated solvent using the standard reference tetramethylsilane (TMS).

***Mass spectrometry***: molecular weights were analyzed in methanol using electrospray ionization-mass spectrometry (ESI-MS; VG Platform, Fisons Instruments, Altrincham, UK). Accurate mass spectra were collected in both positive and negative ion mode.

***Elemental analysis***: elemental CHN analyses were obtained using a Flash 2000 Elemental Analyzer (Thermo Fisher Scientific, Voltaweg, the Netherlands). Simultaneous determination of the elements C, H and N was based on full combustion of the samples at up to 1200 °C in an oxygen atmosphere.

**Photoluminescence (PL) spectroscopy:** the fluorescence intensity of R6G, A-R6G, and R6G-loaded and A-R6G-loaded BU-PPG nanoparticles were determined using a luminescence spectrometer (Hitachi F4500, Tokyo, Japan), using a Xenon lamp at 25 °C.

**Dynamic light scattering (DLS) and zeta potentials:** the surface charge, hydrodynamic diameter, size distribution and polydispersity index (PDI) of aqueous solutions of R6G, A-R6G and the polymers were obtained with a Nano Brook 90Plus PALS instrument (Brookhaven, Holtsville, NY, USA) equipped with a 632 nm He-Ne laser beam and at a fixed scattering angle of 90°. All samples were incubated at 25 °C for at least 30 min before DLS measurements.

**Atomic force microscopy (AFM) and scanning electron microscopy (SEM):** R6G, A-R6G, and R6G-loaded and A-R6G-loaded BU-PPG nanoparticles were prepared by spin coating and vacuum drying at 25 °C for 24 h and their morphologies were assessed using a tapping mode AFM (NX10; AFM Park Systems, Suwon, South Korea) equipped with a standard commercial probe made of silicon (125 nm). The elemental compositions and morphology of the samples were determined using a field-emission SEM (JSM-6500F, JEOL, Tokyo, Japan).

#### ***Preparation of R6G-loaded and A-R6G-loaded BU-PPG nanoparticles***

R6G or A-R6G were encapsulated into BU-PPG using a dialysis method. Briefly, the polymer dissolved in phosphate-buffered saline (PBS; pH 7.4, 10 mM) was added to R6G or A-R6G solution at various polymer/drug ratios (ranging 0.1 to 1 mg), stirred for 24 h, then purified by dialysis against PBS in 1000 Da molecular-weight cut-off dialysis tubing for 24 h. The particle size distributions of R6G-loaded and A-R6G-loaded nanoparticles were characterized by DLS and AFM. DLS particle size measurements were used to evaluate the pH-responsiveness of R6G-loaded and A-R6G-loaded nanoparticles at pH 5.5, 6.5 and 7.4. The drug loading content (DLC)

and loading efficiency (DLE) were analyzed using an UV-Vis spectrophotometer at  $\lambda = 525$  nm (the absorbance intensity of R6G) against a standard calibration curve generated using R6G/MeOH solution, and calculated using the following equations:

$$DLC \% = \frac{\text{Weight of drug loaded in polymeric micelles}}{\text{Weight of drug loaded polymeric micelles}} \times 100$$

$$DLE \% = \frac{\text{Weight of drug loaded in polymeric micelles}}{\text{weight of drug input}} \times 100$$

### ***Long-term kinetic stability***

The structure and stability of R6G-loaded and A-R6G-loaded BU-PPG nanoparticles in aqueous environments were assessed by DLS in the presence of fetal bovine serum (FBS; Thermo Fisher Scientific), which acts as a destabilizing agent. R6G/A-R6G-loaded nanoparticles were mixed with Dulbecco's Modified Eagle Medium (DMEM; pH 7.4, 10 mM; Thermo Fisher Scientific) containing 10% FBS. The variations in the hydrodynamic diameter and distribution of the nanoparticles were monitored over 24 h at 25 °C and 37 °C, respectively.

### ***In vitro drug release assays***

*In vitro* drug release experiments were performed using the dialysis method. Briefly, R6G-loaded and A-R6G-loaded BU-PPG nanoparticles in PBS were placed in 1000 Da cut-off dialysis tubing and dialyzed against large volumes of PBS (10 mM, pH 7.4 and 5.5) with gentle agitation for 48 h at 37 °C or 45 °C. At each time-point (0, 1, 2, 3, 6, 12, 18, 24, 36, and 48 h), an aliquot of dialysis buffer (3 mL) was collected for UV-Vis spectroscopy to quantify the amount of A-R6G (or R6G) released. Fresh PBS (3 mL, pH 5.5 and 7.4) was added to the dialysis tubing to replace the volume of sample removed. The concentrations of R6G/A-R6G were determined by

comparing the absorbance intensity of the collected dialysates against a standard calibration curve. Cumulative A-R6G (or R6G) release from the nanoparticles was determined and plotted as a function of time, using:

$$\text{Cumulative drug release (\%)} = \frac{W_t}{W} \times 100$$

where  $W_t$  represents the amount of A-R6G (or R6G) released at time  $t$ , and  $W$  the total amount of R6G/A-R6G loaded into the nanoparticles.

### ***Cell lines and culture conditions***

Normal mouse embryonic fibroblast NIH/3T3 cells and human cervical carcinoma HeLa cells (ATCC, Manassas, VA, USA) were maintained in DMEM supplemented with 10% FBS and penicillin-streptomycin at 37 °C in a humidified 5% CO<sub>2</sub> atmosphere. Before the experiments, the cells were detached using trypsin-EDTA and an aliquot was re-suspended in PBS containing 0.1% trypan blue (Thermo Fisher, Waltham, MA, USA) to determine the numbers of cells using a hemocytometer.

### ***In vitro cytotoxicity assays***

HeLa cells and NIH/3T3 cells were seeded into 96-well plates at  $1 \times 10^6$  cells per well in 100  $\mu$ L media, and incubated with R6G, A-R6G, or R6G-loaded or A-R6G-loaded nanoparticles at various concentrations (0.1–100  $\mu$ g/mL) for 24 h at 37 °C (pH 7.4), then 20  $\mu$ L of MTT solution (5 mg/mL) in PBS was added to each well, incubated for 4 h, the media containing unreacted dye was carefully removed, the blue formazan crystals were dissolved in 100  $\mu$ L dimethyl sulfoxide solution and the absorbance values were determined using a microplate reader (ELx800; BioTek, Winooski, VT, USA) at 570 nm.

***Analysis of the cellular localization of R6G-loaded and A-R6G-loaded nanoparticles by confocal laser scanning microscopy (CLSM)***

Briefly, HeLa cells and NIH/3T3 cells were seeded into glass-bottomed dishes at an initial density of  $2 \times 10^5$  cells/well in 2 mL DMEM culture media, incubated for 24 h, washed thrice with PBS and the original media was replaced with fresh DMEM medium at pH 7.4 containing R6G-loaded or A-R6G-loaded nanoparticles. The cells were cultured for 3, 6, 12 or 24 h, washed thrice with PBS, fixed in 4% paraformaldehyde for 30 min, stained using 4',6-diamidino-2-phenylindole DAPI for 15 min to visualize nuclei, washed thrice with PBS and examined by confocal laser scanning microscopy (iRiS™ Digital Cell Imaging System; Logos Biosystems, Gyeonggi-do, South Korea).

***Assessment of the cellular uptake of R6G-loaded and A-R6G-loaded nanoparticles by flow cytometry***

Approximately  $2 \times 10^5$  HeLa cells or NIH/3T3 cells were seeded into 6-well plates in DMEM media (2 mL), incubated overnight, then incubated with R6G-loaded or A-R6G-loaded nanoparticles in the culture media at 37 °C for various periods of time (1, 3, 6, 12 or 24 h). The cells were rinsed twice with PBS, detached with 0.25% trypsin-EDTA (0.5 mL, Invitrogen) for 5 min, harvested by centrifugation at 1500 rpm for 3 min, and the cell pellet was washed with PBS and centrifuged, resuspended in ice-cold PBS (0.5 mL) and examined by flow cytometry (FACSAria™ III; BD Biosciences, San Jose, CA, USA). R6G was excited using a 525 nm laser and emitted fluorescence was monitored at 550 nm.


### ***Assessment of apoptotic and necrotic cell death***

The pathways of cell death induced by R6G-loaded and A-R6G-loaded nanoparticles in HeLa cells and NIH/3T3 cells were evaluated by flow cytometry (FACSAria™ III, BD Biosciences, San Jose, CA, USA) using the BV421 Annexin V and Ghost Dye™ Red 780 (GDR780) Detection Kit.<sup>38,39</sup> Approximately  $2 \times 10^5$  HeLa cells or NIH/3T3 cells were seeded into 6-well plates in DMEM (2 mL), incubated overnight, then treated with the drug-loaded nanoparticles in culture media (2 mL) for various periods of time (1, 3 and 6 h). After incubation, the cells were rinsed in PBS, detached using 0.25% trypsin-EDTA, centrifuged at 1500 rpm for 3 min, the cell pellets were washed with PBS, centrifuged, and the cells were resuspended in binding buffer (100  $\mu$ L) in flow cytometer tubes. GDR780 (1  $\mu$ L) was added and the cell suspension was incubated in the dark at room temperature for 15 min, then BV421 Annexin V (5  $\mu$ L) was added and incubated in the dark at room temperature for 30 min, and then binding buffer (400  $\mu$ L) was added and the cells were analyzed by flow cytometry (FACSAria™ III, BD Biosciences). Untreated cultured cells were used as control group for background correction.

### ***Statistical analysis***

Each experiment was performed in triplicate and was repeated at least three times; the mean  $\pm$  standard error ( $\pm$  SD) values are reported.





**Fig. S1:** <sup>1</sup>H NMR spectrum of A-MA in deuterium oxide (D<sub>2</sub>O).





Fig. S2:  $^{13}\text{C}$  NMR spectrum of A-MA in  $\text{D}_2\text{O}$ .


data09 #10-23 RT: 0.08-0.17 AV: 7 NL: 5.03E8  
 T: FTMS + p ESI Full ms [155.0000-500.0000]



**Fig. S3:** Mass spectrum of A-MA.

**Table S1:** Elemental content of A-MA, A-Propylamine and A-R6G.

Compound		N (%)	C (%)	H (%)
A-MA	Found	29.886	49.195	5.011
	Theory	31.664	48.861	5.012
A-Propylamine	Found	33.662	45.977	6.613
	Theory	37.244	50.182	6.511
A-R6G	Found	18.086	63.722	6.371
	Theory	18.113	63.832	6.083



**Fig. S4:**  $^1\text{H}$  NMR spectrum of A-Propylamine in  $\text{D}_2\text{O}$ . The A-Propylamine intermediate still contains some impurities, which may majorly be contributed by the formation of the bisadenine byproduct. However, this reaction still dominates the formation and production of A-Propylamine and can form more than 75% of A-Propylamine based on the integral ratio of proton signals in NMR spectroscopy.






Fig. S5: <sup>13</sup>C NMR spectrum of A-Propylamine in D<sub>2</sub>O.


data10 #11-24 RT: 0.08-0.17 AV: 7 NL: 2.08E8  
T: FTMS + p ESI Full ms [155.0000-500.0000]



**Fig. S6:** Mass spectrum of A-Propylamine.




**Fig. S7a:**  $^1\text{H}$  NMR spectrum of A-R6G in deuterated chloroform ( $\text{CDCl}_3$ ).




**Fig. S7b:** Integration values for the peaks in the <sup>1</sup>H NMR spectrum of A-R6G in CDCl<sub>3</sub>.






**Fig. S8a:**  $^1\text{H}$  NMR spectrum of A-R6G in deuterated dimethyl sulfoxide ( $\text{DMSO-}d_6$ ).




**Fig. S8b:** Integration values for the peaks in the  $^1\text{H}$  NMR spectrum of A-R6G in  $\text{DMSO-}d_6$ .


data11 #10-22 RT: 0.08-0.16 AV: 6 NL: 1.87E8  
T: FTMS + p ESI Full ms [200.0000-1000.0000]




**Fig. S9:** Mass spectrum of A-R6G.



**Fig. S10:** Photograph of A-R6G in PBS (pH 7.4) and aqueous solutions of various pH values after heating at 70 °C for 1 d and standing at 25 °C for 12 h.



**Fig. S11:** AFM images of spin-coated **(a)** R6G and **(b)** A-R6G thin films at 25 °C.



**Fig. S12:** <sup>1</sup>H NMR spectra obtained from <sup>1</sup>H NMR titration experiments of A-R6G/BU-PPG complexes in CDCl<sub>3</sub> at 25 °C. The NH<sub>2</sub> region of the <sup>1</sup>H-NMR spectra of A-R6G after blending with BU-PPG is indicated.





Fig. S13: Benesi-Hildebrand plots for the A-R6G/BU-PPG association in  $\text{CDCl}_3$  at 25 °C.



**Fig. S14:**  $^1\text{H}$  NMR spectra of various concentrations of A-R6G in  $\text{CDCl}_3$  at  $25^\circ\text{C}$ . The  $\text{NH}_2$  region of the  $^1\text{H}$ -NMR spectrum of A-R6G is indicated.








Fig. S15: Benesi-Hildebrand plots for the A-R6G association in  $\text{CDCl}_3$  at 25 °C.

**Table S2:** Drug loading content (DLC) and encapsulation efficiency (EE) of A-R6G-loaded and R6G-loaded BU-PPG nanoparticles.


<b>Carrier:Drug (mg:mg)</b>	<b>R6G/BU-PPG</b>		<b>A-R6G/BU-PPG</b>	
	<b>DLC (wt%)</b>	<b>EE (wt%)</b>	<b>DLC (wt%)</b>	<b>EE (wt%)</b>
1.0:0.1	10.17	81.32	55.32	98.47
1.0:0.2	13.24	68.18	69.63	90.51
1.0:0.3	17.78	62.83	73.06	85.24
1.0:0.6	22.14	49.82	78.04	76.74
1.0:1.0	23.62	44.87	84.28	72.48




**Fig. S16:** DLS intensity mean size distribution curves for A-R6G-loaded and R6G-loaded BU-PPG nanoparticles in aqueous solution.




**Fig. S17:** SEM and AFM images of spin-coated A-R6G-loaded and R6G-loaded BU-PPG films at 25 °C.




**Fig. S18:** Time-dependent DLS measurements of the kinetic stability of A-R6G-loaded and R6G-loaded BU-PPG nanoparticles in DMEM media containing 10% (v/v) FBS at 37 ° C.



**Fig. S19:** MTT cell viability assays of (a) NIH/3T3 cells and (b) HeLa cells after incubation with various concentrations of A-R6G-loaded and R6G-loaded BU-PPG nanoparticles for 24 h.



**Fig. S20:** CLSM fluorescence images of (a) NIH/3T3 and (b) HeLa cells incubated with R6G-loaded BU-PPG nanoparticles at pH 7.4 and 37 °C for various periods of time. The white scale bars in all CLSM images represent 20 μm.



**Fig. S21:** Fluorescence intensities of NIH/3T3 cells and HeLa cells after incubation with A-R6G-loaded BU-PPG nanoparticles at pH 7.4 and 37 °C for various periods of time.